Abstract

US biotech sector revenue is estimated to have grown on average >10% each year over the past decade—much faster than the rest of the economy. A more comprehensive assessment of biotech's economic contribution, however, will require improved data collection, classification and analysis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call